Nvidia faces two imminent problems

After the company reported better-than-expected quarterly earnings last night… Experts have high expectations that the stock could soon shoot past $500 per share. But if you plan to trade the stock, there are two imminent problems that could erase any money you put into Nvidia over the next six to twelve months. Details here + one asset that handed me my first $1 million in trading profits.   The Incredible Thing About Moderna's 15x Return  Before Moderna went public in 2018, it had no products on the market. It was a microcap focused on the once-obscure niche of messenger RNA products… And its share price stayed well below $30 for its first year of trading. But once news leaked that its COVID vaccine would win FDA approval in December 2020, the stock went on a tear from $29 in March 2020 to $451 in September 2021. That would be 15x your money if you got in on the ground floor. It's an excellent reminder of the groundfloor advantage in biotech, and if you missed the big biotech profits earlier this year, a more lucrative opportunity is unfolding right now… See the results of a new trading investigation for details on how to profit. To big profits and beyond,     Anthony S. Energy Expert at Big Energy Profits In Case You Missed It:   ChatGPT — Who are we kidding? He lost $4 million and three years of work. How to profit when institutional players tip their hands. team1@hawkeyetraders.com bigenergyprofits.com Call us: (888) 233-8598 DISCLAIMER: * Futures, stocks, and spot currency trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures, stocks, and forex markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures, stocks or forex. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. Past performance of indicators or methodology are not necessarily indicative of future results. CFTC Regulation 4.41 These results are based on simulated or hypothetical performance results that have certain inherent limitations. Unlike the results shown in an actual performance record, these results do not represent actual trading. Also, because these trades have not actually been executed, these results may have under-or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated or hypothetical trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profits or losses similar to these being shown. We'll always treat your personal information with the utmost care and will never sell it to third parties. You can find out more about what data we hold about you, why we need it, and how we keep that information safe in our Privacy Policy.

If you wish to stop receiving our emails or change your subscription options, please manage your subscription.

14422 Shoreside Way, Suite 110-160, Winter Garden, FL 3478, US